Details

Autor(en) / Beteiligte

• Corr, Bradley
• Thomas, Samantha
• Haight, Paulina
• Stock, Elizabeth
• Floyd, Jessica
• Borden, Lindsay
• Tunnage, Irina
• Secord, Angeles Alvarez
• Arend, Rebecca
• Jackson, Amanda
• Wright, Jason
• Konecny, Gottfried
• Castellano, Tara
• Ko, Emily
• Podwika, Sarah
• Backes, Floor
• Spinosa, Daniel
• Mullen, Margaret
• Washington, Christina
• Pothuri, Bhavana
• Smitherman, Carsen
• Harsono, Alfonsus
• Khadraoui, Hanaa
• Suzuki, Yukio
• Salani, Ritu
• Powell, Kristina
• Subbarao, Shalini
• Gaillard, Stephanie

Titel

PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability

Ist Teil von

• International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A43-A44

Ort / Verlag

Oxford: BMJ Publishing Group Ltd

Erscheinungsjahr

2023

Link zum Volltext

Beschreibungen/Notizen

• IntroductionKeynote-775 defined the SOC for MMRp recurrent EC. AEs with recommended dosing of lenvatinib/pembrolizumab led to dose reductions in 66.5% of patients. Real world prescription patterns vary significantly from clinical trial. We describe prescribing patterns and outcomes across a multi-institutional consortium.MethodsA national multidisciplinary consortium was utilized to study patients with advanced/recurrent EC treated with lenvatinib/pembrolizumab. Treatment decisions were based on the physician’s recommendation.Results217 patients across 14 institutions were identified. Histologic subtypes were 34.1% endometrioid, 39.6% serous, 9.7% carcinosarcoma, 10.1% mixed, and 2.8% clear cell. 82.9% were MMRp and 4.6% were MMRd. Median dose intensity of lenvatinib was 14 mg. Lenvatinib starting dose was 20 mg in 17.1%, 18 mg in 12.9%, 14 mg in 41%, 10 mg in 15.7%. Rates of any grade >=3 AE related to lenvatinib were 20 mg (13.5%), 18 mg (17.9%), 14 mg (7.9%), 10 mg (17.6%) (p=0.31). Pembrolizumab dosing was 200 mg Q3W in 85.6% and 400 mg Q6W in 6.5%. ORR (p=0.38), PFS (p=0.97) & OS (p=0.31) were similar in White vs. Black patients. ORR in relation to Lenvatinib starting dose 20 mg, 18 mg, 14 mg, 10 mg was 27%, 35.7%, 39.3%, 44.1% (p=0.08). In relation to Lenvatinib starting dose, 12-month PFS rates were 40%, 35%, 35%, 47% respectively (p=0.92), 12-month OS were 59%, 66%, 56%, 51% respectively (p=0.79), and median duration of therapy was 5.1, 4.1, 4.8, 4.6 months respectively (p=0.52).Conclusion/ImplicationsIn a real-world analysis, the predominant starting dose is 14 mg lenvatinib and 200 mg pembrolizumab. Grade >=3 AE’s, 12-month PFS/OS, ORR & duration of therapy related to lenvatinib starting dose were not statistically different. Abstract PR023/#503 Figure 1Abstract PR023/#503 Figure 2